Merck's Keytruda wins FDA 'breakthrough' tag in colorectal cancer; Allergan nabs bowel drug rights in Europe;

> Merck & Co. ($MRK) won the FDA's breakthrough designation for its immuno-oncology therapy Keytruda in colorectal cancer; the drug is already approved to treat melanoma and lung cancer. Release

> Allergan ($AGN) bought the rights to Constella (linaclotide) in 40-plus countries, including major European markets, from Spain's Almirall; the drug is sold as Linzess in the U.S. Report

> New blockbuster drugs will drive big growth in the multiple myeloma market, GlobalData says, to $22.4 billion in sales by 2023, up from $8.9 billion in 2014. Report

> GlaxoSmithKline ($GSK), Roche ($RHHBY) and Sanofi ($SNY) all have major investor presentations this week, highlighting their R&D pipelines, and, in Sanofi's case, a new strategy from its new CEO, Olivier Brandicourt. Report

> Eisai said it's presenting data from an Asian Fycompa study in patients with difficult-to-treat partial-onset seizures, in which the drug topped placebo at cutting the frequency of seizures. Release

And Finally... The Novartis Foundation and its partners launched a hypertension screening effort in Ghana as part of a two-year test of an "innovative healthcare model" designed to control high blood pressure. Release

Suggested Articles

The Trump administration's ad blitz to allay pandemic fears took another bizarre turn with reports of a Santa Claus recruitment scheme gone awry.

Novartis is taking its MBC campaign to Instagram with a newly launched video series as part of the five-year “Make Your Dialogue Count” effort.

FDA researchers uncover more concerns and fears among front-line workers and minority groups about a COVID-19 vaccine.